Maternal Outcomes and Clinical Characteristics of COVID-19 in Korean Pregnant Women during the Early Period of the Pandemic

Youseung Chung; Dong-Hwan Choi; John G. Ilagan; Juneyoung Lee; Young Kyung Yoon

doi:10.3346/jkms.2021.36.e290

Journal List > J Korean Med Sci > v.36(41) > 1147956

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Chung, Choi, Ilagan, Lee, and Yoon: Maternal Outcomes and Clinical Characteristics of COVID-19 in Korean Pregnant Women during the Early Period of the Pandemic

Brief Communication

Infectious Diseases, Microbiology & Parasitology

Journal of Korean Medical Science 2021; 36(41): e290.

Published online: 12 October 2021

DOI: https://doi.org/10.3346/jkms.2021.36.e290

Maternal Outcomes and Clinical Characteristics of COVID-19 in Korean Pregnant Women during the Early Period of the Pandemic

Youseung Chung¹

, Dong-Hwan Choi²

, John G. Ilagan³

, Juneyoung Lee²

, Young Kyung Yoon¹

¹Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

²Department of Biostatistics, Korea University College of Medicine, Seoul, Korea.

³Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.

Address for Correspondence: Young Kyung Yoon, MD, PhD. Division of Infectious Diseases, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, Seoul 02841, Korea. young7912@korea.ac.kr

Received 16 July 2021 Accepted 5 October 2021

The Korean Academy of Medical Sciences

https://creativecommons.org/licenses/by-nc/4.0/

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The present study aimed to compare the clinical characteristics and outcomes between pregnant women and non-pregnant women of childbearing age (20–49 years old) diagnosed with coronavirus disease 2019 (COVID-19) during the initial stage of the COVID-19 pandemic in the Republic of Korea. This nationwide observational study included the information of COVID-19 patients collected by the Korea Disease Control and Prevention Agency from January 2020 to April 2021. Among 5,647 COVID-19 patients, 2,444 (43.3%) were women of childbearing age and 19 were pregnant. None of the pregnant women died. However, 4 deaths occurred among non-pregnant women aged 20–49 years. None of the 19 pregnant women with COVID-19 were admitted to the intensive care unit: they were admitted to the general ward, and none of them required supplemental oxygen. In conclusion, none of the pregnant women with COVID-19 experienced severe infection or death, unlike non-pregnant women of childbearing age.

Graphical Abstract

Keywords: COVID-19, SARS-CoV-2, Pregnancy

The ongoing coronavirus disease 2019 (COVID-19) pandemic is one of the most significant public health threats in modern history and has changed many aspects of medical care and the daily lives of various people. Until recently, many of the response strategies against this pandemic have been based on previous experience with other highly pathogenic coronaviruses such as severe acute respiratory syndrome and Middle East respiratory syndrome.1 2 As the virologic, epidemiologic, and clinical aspects of this emerging infectious disease are gradually revealed, the effects of severe acute respiratory syndrome coronavirus-2 on a possibly vulnerable subpopulation are currently investigated. The anatomic, physiologic, and immunologic changes that occur as a normal part of pregnancy may cause pregnant women to be more susceptible and vulnerable to viral infections.3

However, the susceptibility of pregnant women to COVID-19 and related complications remains controversial and unresolved. Data on the clinical impact of COVID-19 on pregnant women in the Republic of Korea (ROK) are limited.4 5 6 7 8 This information is critical to assessing the risk-benefit of a COVID-19 vaccine, whose Food and Drug Administration approval for use among pregnant women is still pending. Therefore, this study aimed to investigate the clinical characteristics and outcomes in pregnant women diagnosed with COVID-19 during the early stage of the COVID-19 pandemic.

This observational multicenter cohort study was performed using a nationwide database obtained from the medical records from multiple Korean hospitals. In collaboration with Korea Disease Control and Prevention Agency (KDCA) and the National Medical Center, the demographic, epidemiological, and early clinical information of confirmed COVID-19 patients were collected from the government registry from January 2020 to April 2021. After extracting the relevant information from the KDCA database, we compared the maternal outcomes and clinical characteristics of pregnant women diagnosed with COVID-19 with those of non-pregnant women of childbearing age at the onset of the pandemic in Korea. All patients underwent reverse-transcription polymerase chain reaction (RT-PCR) to confirm the diagnosis of COVID-19.

Data on age, sex, body mass index (BMI), clinical symptoms at the time of diagnosis (pharyngitis, runny nose, myalgia, fatigue, dyspnea, headache, change of consciousness, nausea, and diarrhea), intensive care unit (ICU) admission, supplemental oxygen requirement, mechanical ventilation, multiple organ failure, death, comorbidities (diabetes, hypertension, chronic heart disease, asthma, chronic obstructive pulmonary disease, chronic kidney disease, cancer, chronic liver disease, autoimmune disease, and dementia), and complete blood count (CBC) were obtained. Statistical tests including χ² test, Fisher's exact test, Mantel-Haenszel test, and Mann-Whitney U test were used according to the characteristics of the data.

From January 2020 to April 2021, 5,647 COVID-19 patients were included in the registry. Among these patients, 3,327 (58.9%) were women, and 2,444 were women of childbearing age. A total of 19 patients were pregnant women: 5 (26.3%) were aged 20–29 years; 13 (68.4%) were aged 30–39 years, and 1 (5.3%) was aged 40–49 years.

The mortality rates among the total study patients and female patients were 4.3% and 3.5%, respectively. No deaths occurred among pregnant women, while four (0.16%) deaths occurred among women of childbearing age. The median period (interquartile range, IQR) from COVID-19 diagnosis to death in women of childbearing age was 23 (11–37) days. In all patients, the duration between diagnosis of COVID-19 and release from isolation was 23 (18–31) days or 24 (18–32) days for women of childbearing age, and 22 (18–38) days for pregnant women.

All pregnant women in the case group were admitted to the general ward, whereas 21 patients in the control group (0.87%) were admitted to the ICU (P = 1.000). None of the pregnant women required supplemental oxygen, while 70 non-pregnant women of childbearing age required supplemental oxygen with or without mechanical ventilation.

None of the pregnant women had comorbidities, while the control group had various pre-existing conditions (Table 1). No significant difference was found in the clinical symptoms between the two groups (Table 1). Six of the 19 pregnant women were asymptomatic.

Meanwhile, significant differences were observed in the CBC results between pregnant women and non-pregnant women: hemoglobin (g/dL) [median (IQR); 12.3 (11.4–13.3) vs. 13.8 (12.8–15.1), P < 0.001], white blood cell (WBC) count (cells/µL) [7,740 (6,410–9,300) vs. 5,640 (4,425–7,080), P < 0.001], and lymphocyte (%) [18.9 (17.2–30.5) vs. 30.7 (24.0–37.7), P < 0.001].

This observational multicenter study demonstrated that all 19 pregnant women with confirmed COVID-19 did not exhibit worsening of disease compared with that in non-pregnant women. To our knowledge, this is the first study to compare the morbidity and mortality rates of COVID-19 pregnant women with those of non-pregnant women of childbearing age in the ROK. Focusing on the clinical impact of COVID-19 during pregnancy can aid physicians and policy-makers in the rational prioritization of COVID-19 vaccination strategies and improving the management of COVID-19 cases. Specifically, the clinical data of domestic groups at higher risk for COVID-19 are critical for improving national preparedness and response.

Previous research provided contradictory findings regarding the increased risk for critical illness and mortality resulting from COVID-19 during pregnancy. The physiologic and immunologic changes that occur during pregnancy may increase pregnant women's vulnerability to severe infection. Previous studies suggested that pregnancy is associated with severe or critical COVID-19.9 10 11 12 Considering the mortality rate in pregnant women with COVID-19 described in a Brazilian study, the effect of comorbid conditions and the specific viral strain may be more significant than the pregnancy status in determining clinical severity.13 Previous observational studies noted that majority of pregnant patients do not experience severe or critical COVID-19.6 14 15 16 17 18 19 20 21 22 23 Sentilhes et al.24 reported that maternal age, obesity, hypertension, or diabetes may increase the risk in pregnant women with COVID-19. Because none of the pregnant women included in our study had comorbidities, further analysis in this regard was not possible.

In previous studies, the clinical outcomes associated with COVID-19 did not appear to be worse in pregnant women compared with those in the general population.6 14 15 16 17 18 19 20 21 22 23 However, data are still limited and the sex disparities in clinical severity and mortality of COVID-19 may be a result of the sex differences in comorbidities and behaviors. Men with COVID-19 appear to have worse clinical outcomes than those in women with COVID-19.25 26 27 28 Furthermore, older age is strongly associated with increased mortality in COVID-19 patients.28 29 30 Considering that women have better outcomes than those in men,27 28 the hormonal profile and associated physiologic changes in young pregnant women may prevent worsening of the disease. However, the physiologic reserves and immunity are reduced in this patient group.

Conflicting studies suggest that COVID-19 during pregnancy may or may not lead to an increased risk of pregnancy complications such as preeclampsia, preterm birth, miscarriage, and perinatal death.17 19 21 31 32 33 34 Numerous factors including medical comorbidities, physiologic changes in pregnancy, and baseline susceptibility to infection in addition to social factors such as limited access to care and difficulties with social isolation may negatively impact both maternal and fetal outcomes. Further studies among Korean patients are required to explain the outcomes observed in our population.

In women with normal pregnancy, the leukocyte count was higher and the lymphocyte percentage was lower among pregnant women with COVID-19 than that among non-pregnant controls. A previous meta-analysis demonstrated a significant correlation between increased leukocyte count and decreased lymphocyte count among patients with severe cases of COVID-19 compared with those with mild cases.35 However, these laboratory findings may not be associated with worsening disease, but may result from other benign processes. In severe cases of COVID-19, intensive inflammation may lead to destruction of lymphatic tissues, lymphocyte apoptosis, and direct lymphocyte infection, in addition to lymphocyte inhibition due to metabolic disorders, including lactic acidosis.36 On the contrary, pregnancy may cause immunomodulation resulting in the recognition and destruction of similar self-antigens.

During the initial stage of the pandemic, pregnant women in the ROK were hospitalized and managed according to the national policy requiring inpatient isolation, unlike other countries. These measures were implemented to prevent the lack of prenatal care, surveillance, and adequate treatment for those with COVID-19. This policy may explain why the severity of infection was similar in pregnant and non-pregnant patients.

Our study has several limitations. This analysis only included a very small number of pregnant women who did not have underlying diseases or complications associated with pregnancy. Furthermore, our study did not investigate the delivery mode, gestational age at the time of delivery, and frequency of vertical transmission or neonatal outcomes due to the limited data extracted from the government-operated registry.

In conclusion, pregnant women with COVID-19 infection were not at higher risk of severe or critical disease that would require supplemental oxygen, ICU admission, or mechanical ventilation. None of the pregnant women in our cohort experienced severe infection sequelae including sepsis, multiple organ failure, or maternal mortality. However, further analysis of multinational pregnancy cohorts is warranted to improve our understanding and strategies of managing COVID-19 in pregnant women.

Ethics statement

The study protocol was approved by the Institutional Review Board (IRB) of Korea University Anam Hospital (IRB no. 2020AN0408). The need for obtaining informed consent was waived due to the retrospective nature of the study.

ACKNOWLEDGMENTS

We greatly appreciate the efforts of all the medical personnel and their families who are fighting tirelessly at the forefront of this pandemic. We thank the members of the Korea Disease Control and Prevention Agency who collected and released the clinical and epidemiologic information of patients with confirmed COVID-19.

Notes

Funding: This research was supported by the Korea University Medicine funds raised for coronavirus disease 19 research (Grant No. O2001221). The funding agency had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Disclosure: All authors have no potential conflicts of interest to declare.

Author Contributions:

Conceptualization: Yoon YK.
Data curation: Choi DH.
Formal analysis: Choi DH.
Funding acquisition: Yoon YK.
Project administration: Yoon YK.
Software: Choi DH.
Supervision: Ilagen JG, Lee J, Yoon YK.
Validation: Chung Y, Yoon YK.
Visualization: Chung Y.
Writing - original draft: Chung Y.
Writing - review & editing: Yoon YK.

References

1. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. Am J Obstet Gynecol. 2020; 222(5):415–426. PMID: 32105680.

2. Chen D, Yang H, Cao Y, Cheng W, Duan T, Fan C, et al. Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection. Int J Gynaecol Obstet. 2020; 149(2):130–136. PMID: 32196655.

3. Alberca RW, Pereira NZ, Oliveira LM, Gozzi-Silva SC, Sato MN. Pregnancy, viral infection, and COVID-19. Front Immunol. 2020; 11:1672. PMID: 32733490.

4. Lee EK, Kim WD, Lee DW, Lee SA. Management of the first newborn delivered by a mother with COVID-19 in South Korea. Clin Exp Pediatr. 2020; 63(9):373–375. PMID: 32683810.

5. Bae JG, Ha JK, Kwon M, Park HY, Seong WJ, Hong SY. A case of delivery of a pregnant woman with COVID-19 infection in Daegu, Korea. Obstet Gynecol Sci. 2020; 63(6):745–749. PMID: 33012160.

6. Jang WK, Lee SY, Park S, Ryoo NH, Hwang I, Park JM, et al. Pregnancy outcome, antibodies, and placental pathology in SARS-CoV-2 infection during early pregnancy. Int J Environ Res Public Health. 2021; 18(11):5709. PMID: 34073422.

7. Lee DH, Lee J, Kim E, Woo K, Park HY, An J. Emergency cesarean section performed in a patient with confirmed severe acute respiratory syndrome coronavirus-2 -a case report. Korean J Anesthesiol. 2020; 73(4):347–351. PMID: 32229802.

8. Jin JH, Kim Y, Yoo J, Kim EH, Yoon SW. Two cases of SARS-CoV-2-positive mothers and their newborns in Korea. Infect Chemother. 2021; 53:e41. Epub ahead of print.

9. Capobianco G, Saderi L, Aliberti S, Mondoni M, Piana A, Dessole F, et al. COVID-19 in pregnant women: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020; 252:543–558. PMID: 32713730.

10. Khan DS, Pirzada AN, Ali A, Salam RA, Das JK, Lassi ZS. The differences in clinical presentation, management, and prognosis of laboratory-confirmed COVID-19 between pregnant and non-pregnant women: a systematic review and meta-analysis. Int J Environ Res Public Health. 2021; 18(11):5613. PMID: 34074005.

11. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: a systematic review of 108 pregnancies. Acta Obstet Gynecol Scand. 2020; 99(7):823–829. PMID: 32259279.

12. Li N, Han L, Peng M, Lv Y, Ouyang Y, Liu K, et al. Maternal and neonatal outcomes of pregnant women with coronavirus disease 2019 (COVID-19) pneumonia: a case-control study. Clin Infect Dis. 2020; 71(16):2035–2041. PMID: 32249918.

13. Takemoto ML, Menezes MO, Andreucci CB, Nakamura-Pereira M, Amorim MM, Katz L, et al. The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting. Int J Gynaecol Obstet. 2020; 151(1):154–156. PMID: 32644220.

14. Figueiro-Filho EA, Yudin M, Farine D. COVID-19 during pregnancy: an overview of maternal characteristics, clinical symptoms, maternal and neonatal outcomes of 10,996 cases described in 15 countries. J Perinat Med. 2020; 48(9):900–911. PMID: 33001856.

15. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-COV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2020; 144(7):799–805. PMID: 32180426.

16. Zhang L, Dong L, Ming L, Wei M, Li J, Hu R, et al. Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, China. BMC Pregnancy Childbirth. 2020; 20(1):394. PMID: 32641013.

17. Yan J, Guo J, Fan C, Juan J, Yu X, Li J, et al. Coronavirus disease 2019 in pregnant women: a report based on 116 cases. Am J Obstet Gynecol. 2020; 223(1):111.e1–111.14. PMID: 32335053.

18. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020; 395(10226):809–815. PMID: 32151335.

19. Bellos I, Pandita A, Panza R. Maternal and perinatal outcomes in pregnant women infected by SARS-CoV-2: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021; 256:194–204. PMID: 33246205.

20. Huntley BJ, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP. Rates of maternal and perinatal mortality and vertical transmission in pregnancies complicated by severe acute respiratory syndrome coronavirus 2 (SARS-Co-V-2) infection: a systematic review. Obstet Gynecol. 2020; 136(2):303–312. PMID: 32516273.

21. Cardona-Pérez JA, Villegas-Mota I, Helguera-Repetto AC, Acevedo-Gallegos S, Rodríguez-Bosch M, Aguinaga-Ríos M, et al. Prevalence, clinical features, and outcomes of SARS-CoV-2 infection in pregnant women with or without mild/moderate symptoms: results from universal screening in a tertiary care center in Mexico City, Mexico. PLoS One. 2021; 16(4):e0249584. PMID: 33886590.

22. Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein K, et al. Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM. 2020; 2(2):100118. PMID: 32292903.

23. Blitz MJ, Grünebaum A, Tekbali A, Bornstein E, Rochelson B, Nimaroff M, et al. Intensive care unit admissions for pregnant and nonpregnant women with coronavirus disease 2019. Am J Obstet Gynecol. 2020; 223(2):290–291. PMID: 32387323.

24. Sentilhes L, De Marcillac F, Jouffrieau C, Kuhn P, Thuet V, Hansmann Y, et al. Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. Am J Obstet Gynecol. 2020; 223(6):914.e1–914.15. PMID: 32553908.

25. Alwani M, Yassin A, Al-Zoubi RM, Aboumarzouk OM, Nettleship J, Kelly D, et al. Sex-based differences in severity and mortality in COVID-19. Rev Med Virol. Forthcoming. 2021; DOI: 10.1002/rmv.2223.

26. Foresta C, Rocca MS, Di Nisio A. Gender susceptibility to COVID-19: a review of the putative role of sex hormones and X chromosome. J Endocrinol Invest. 2021; 44(5):951–956. PMID: 32936429.

27. Mohamed MS, Moulin TC, Schiöth HB. Sex differences in COVID-19: the role of androgens in disease severity and progression. Endocrine. 2021; 71(1):3–8. PMID: 33179220.

28. Jang SY, Seon JY, Eun BL, Koh SB, Yoo JH, Lee WY, et al. Risk factors of outcomes of COVID-19 patients in Korea: focus on early symptoms. J Korean Med Sci. 2021; 36(18):e132. PMID: 33975399.

29. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2020; 92(10):1875–1883. PMID: 32441789.

30. Chinnadurai R, Ogedengbe O, Agarwal P, Money-Coomes S, Abdurrahman AZ, Mohammed S, et al. Older age and frailty are the chief predictors of mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting- a cohort study. BMC Geriatr. 2020; 20(1):409. PMID: 33066750.

31. Akhtar H, Patel C, Abuelgasim E, Harky A. COVID-19 (SARS-CoV-2) Infection in pregnancy: a systematic review. Gynecol Obstet Invest. 2020; 85(4):295–306. PMID: 32728006.

32. Abedzadeh-Kalahroudi M, Sehat M, Vahedpour Z, Talebian P, Haghighi A. Clinical and obstetric characteristics of pregnant women with Covid-19: a case series study on 26 patients. Taiwan J Obstet Gynecol. 2021; 60(3):458–462. PMID: 33966728.

33. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020; 2(2):100107. PMID: 32292902.

34. Mullins E, Hudak ML, Banerjee J, Getzlaff T, Townson J, Barnette K, et al. Pregnancy and neonatal outcomes of COVID-19: coreporting of common outcomes from PAN-COVID and AAP-SONPM registries. Ultrasound Obstet Gynecol. 2021; 57(4):573–581. PMID: 33620113.

35. Huang G, Kovalic AJ, Graber CJ. Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. Emerg Infect Dis. 2020; 26(8):1839–1841. PMID: 32384045.

36. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020; 5(1):33. PMID: 32296069.

Table 1

Overview of the demographic and clinical characteristics of patients with COVID-19

Demographic characteristics		Total male and female patients, non-pregnant (n = 5,628)	Total non-pregnant women (n = 3,308)	Non-pregnant women aged 20 to 49 years (n = 2,425)	Pregnant women (n = 19)	P value^a	P value^b	P value^c
Age, yr						< 0.001^d	< 0.001^d	< 0.001^d
	20–29	1,119 (46.14)	569 (41.72)	1,119 (46.14)	5 (26.32)
	30–39	564 (23.26)	295 (21.63)	564 (23.26)	13 (68.42)
	40–49	742 (30.6)	500 (36.66)	742 (30.6)	1 (5.26)
BMI, kg/m²						0.729^e	0.831^e	0.919^e
	< 18.5	260 (4.62)	173 (5.23)	106 (4.37)	1 (5.26)
	18.5–22.9	1,867 (33.17)	1,253 (37.88)	923 (38.06)	8 (42.11)
	23.0–24.9	1,039 (18.46)	552 (16.69)	410 (16.91)	2 (10.53)
	25.0–29.9	1,052 (18.69)	476 (14.39)	461 (19.01)	3 (15.79)
	≥ 30	208 (3.7)	109 (3.3)	132 (5.44)	1 (5.26)
Comorbidities
	Diabetes mellitus	691 (12.28)	366 (11.06)	69 (2.85)	0 (0.00)	0.157^e	0.258^e	1.000^e
	Hypertension	1,201 (21.34)	695 (21.01)	118 (4.87)	0 (0.00)	0.021^e	0.020^e	1.000^e
	Heart failure	59 (1.05)	37 (1.12)	2 (0.08)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Cardiovascular diseases	179 (3.18)	92 (2.78)	17 (0.7)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Asthma	128 (2.27)	82 (2.48)	46 (1.9)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Chronic obstructive pulmonary disease	40 (0.71)	15 (0.45)	2 (0.08)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Chronic kidney disease	55 (0.98)	29 (0.88)	7 (0.29)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Malignancy	145 (2.58)	96 (2.9)	28 (1.15)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Chronic liver disease	83 (1.47)	35 (1.06)	25 (1.03)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Autoimmune disease	38 (0.68)	26 (0.79)	6 (0.25)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Dementia	224 (3.98)	153 (4.63)	1 (0.04)	0 (0.00)	1.000^e	1.000^e	1.000^e
Mortality
	Yes	241 (4.28)	114 (3.45)	4 (0.16)	0 (0.00)	-	-	-
	Time between diagnosis of COVID-19 and death, median days, IQR	11 (6, 20)	10 (6, 19)	23 (10.5, 37)	-
	No	5,387 (95.72)	3,194 (96.55)	2,421 (99.84)	19 (100.00)	0.836^f	0.852^f	0.541^f
	Time between diagnosis of COVID-19 and release from isolation, median days, IQR	24 (18, 32)	24 (18, 32)	23 (18, 31)	22 (18, 38)
Admission						1.000^e	1.000^e	1.000^e
	Intensive care unit	189 (3.36)	74 (2.24)	21 (0.87)	0 (0.00)
	General ward	5,410 (96.13)	3,216 (97.22)	2,404 (99.13)	19 (100)
Clinical severity of COVID-19						0.596^e	0.564^e	0.793^e
	No oxygen therapy	4,455 (79.16)	2,648 (80.05)	2,198 (90.64)	19 (100)
	Nasal cannula	469 (8.33)	268 (8.1)	60 (2.47)	0 (0.00)
	Oxygen mask	43 (0.76)	20 (0.6)	5 (0.21)	0 (0.00)
	Non-invasive ventilation	33 (0.59)	16 (0.48)	4 (0.16)	0 (0.00)
	Invasive ventilation	19 (0.34)	9 (0.27)	1 (0.04)	0 (0.00)
	Multi-organ failure or ECMO	11 (0.2)	4 (0.12)	0 (0.00)	0 (0.00)
Symptoms
	Fever	1,305 (23.19)	784 (23.7)	512 (21.11)	3 (15.79)	0.591^e	0.590^e	0.780^d
	Cough	2,341 (41.6)	1,423 (43.02)	990 (40.82)	6 (31.58)	0.374^e	0.312^e	0.408^e
	Sputum	1,619 (28.77)	1,027 (31.05)	659 (27.18)	6 (31.58)	0.788^e	0.961^e	0.667^e
	Pharyngitis	881 (15.65)	591 (17.87)	449 (18.52)	2 (10.53)	0.756^e	0.556^e	0.555^e
	Rhinorrhea	621 (11.03)	382 (11.55)	327 (13.48)	3 (15.79)	0.459^e	0.475^e	0.735^e
	Myalgia	926 (16.45)	600 (18.14)	387 (15.96)	4 (21.05)	0.539^e	0.764^e	0.529^e
	Fatigue	234 (4.16)	134 (4.05)	83 (3.42)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Dyspnea	666 (11.83)	403 (12.18)	164 (6.76)	0 (0.00)	0.156^e	0.156^e	0.635^e
	Headache	967 (17.18)	668 (20.19)	454 (18.72)	2 (10.53)	0.759^e	0.398^e	0.555^e
	Altered mental status	35 (0.62)	19 (0.57)	2 (0.08)	0 (0.00)	1.000^e	1.000^e	1.000^e
	Nausea or vomiting	244 (4.34)	176 (5.32)	83 (3.42)	1 (5.26)	0.570^e	1.000^e	0.486^e
	Diarrhea	518 (9.2)	317 (9.58)	239 (9.86)	1 (5.26)	1.000^e	1.000^e	1.000^e
Complete blood cell count
	Hemoglobin, median g/dL, IQR	13.3 (12.2, 14.4)	12.9 (11.9, 13.6)	13.8 (12.8, 15.1)	12.3 (11.4, 13.3)	0.006^f	0.136^f	< 0.001^f
	Hematocrit, median %, IQR	39.2 (36.4, 42.4)	38.1 (35.6, 40.4)	41 (38, 44.1)	36 (34.6, 39.5)	0.005^f	0.096^f	< 0.001^f
	Lymphocyte, median %, IQR	28.9 (21.3, 36.5)	30.1 (22.8, 37.3)	30.7 (24, 37.7)	18.9 (17.2, 30.5)	0.003^f	< 0.001^f	< 0.001^f
	Platelets, median × 10³/μL, IQR	228 (180, 284)	236 (188, 293)	238.5 (197, 285)	238 (223, 287)	0.056^f	0.158^f	0.167^f
	White blood cell, median count/μL, IQR	5,695 (4,450, 7,170)	5,660 (4,390, 7,140)	5,640 (4,425, 7,080)	7,740 (6,410, 9,300)	< 0.001^f	< 0.001^f	< 0.001^f

BMI = body mass index, COVID-19 = coronavirus disease-19, ECMO = extracorporeal membrane oxygenation, IQR = interquartile range.

^aComparison between pregnant women and total patients except pregnant women; ^bComparison between pregnant women and non-pregnant women; ^cComparison between pregnant women and women aged 20–49 years except pregnant women; ^dχ² test was used for testing; ^eFisher's exact test was used for testing; ^fMann-Whitney U test (Wilcoxon two-sample test) was used for testing.

TOOLS

Similar articles